POP-OUT | CLOSE

An Information Portal to 105339 Biological Macromolecular Structures

 
RAPAMYCIN IMMUNOSUPPRESSANT DRUG
 
RAP is found in 14 entries
RAP
  •   Chemical Component Summary   Hide
    Name RAPAMYCIN IMMUNOSUPPRESSANT DRUG
    Identifiers (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
    Formula C51 H79 N O13
    Molecular Weight 914.17 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key QFJCIRLUMZQUOT-HPLJOQBZSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00877   (Different stereochemistry)
    Name Sirolimus
    Groups
    • approved
    • investigational
    Description A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. [PubChem]
    Synonyms
    • (-)-Rapamycin
    • Rapamycin
    Brand names Rapamune
    Affected organism Humans and other mammals
    Indication For the prophylaxis of organ rejection in patients receiving renal transplants.
    Pharmacology Sirolimus, a macrocyclic lactone produced by <i>Streptomyces hygroscopicus</i>, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.
    Mechanism of action Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.
    Route of administration Oral
    Categories
    • Immunosuppressive Agents
    • Antifungal Agents
    • Anti-Bacterial Agents
    • Antibiotics, Antineoplastic
    • Macrolides
    ATC-Code L04AA10
    AHFS-Code 92:00.00
    CAS number 53123-88-9
    Targets
    Name Sequence search Pharmacological action Actions
    Peptidyl-prolyl cis-trans isomerase FKBP1A   Search  yes other
    Fibroblast growth factor 2   Search  yes other/unknown
    Serine/threonine-protein kinase mTOR   Search  yes inhibitor
     
Ligand Image